REQUEST A DEMO
Total
USD $0.00
Search more companies

Vitamed Pharmaceuticals Sp. z o.o. (Poland)

Main Activities: Other Miscellaneous Nondurable Goods Merchant Wholesalers
Full name: Vitamed Pharmaceuticals Sp. z o.o. Profile Updated: April 19, 2023
Buy our report for this company USD 19.99 Most recent financial data: 2022 Available in: English & Polish Download a sample report

Vitamed Pharmaceuticals Sp. z o.o. is based in Poland. The head office is in Smardzewice. It operates in the Other Miscellaneous Nondurable Goods Merchant Wholesalers industry. It was established on June 23, 2020. From the latest financial highlights, Vitamed Pharmaceuticals Sp. z o.o. reported a net sales revenue increase of 24.69% in 2022. There was a total growth of 21.14% in Vitamed Pharmaceuticals Sp. z o.o.’s total assets over the same period. The net profit margin of Vitamed Pharmaceuticals Sp. z o.o. increased by 3.21% in 2022.

Headquarters
Ul. Posla Jozefa Ostrowskiego 24
Smardzewice; Lodzkie; Postal Code: 97-213

Contact Details: Purchase the Vitamed Pharmaceuticals Sp. z o.o. report to view the information.

Basic Information
Outstanding Shares:
Purchase the Vitamed Pharmaceuticals Sp. z o.o. report to view the information.
Registered Capital:
Purchase the Vitamed Pharmaceuticals Sp. z o.o. report to view the information.
Incorporation Date:
June 23, 2020
Key Executives
Purchase this report to view the information.
President
Purchase this report to view the information.
Proxy
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Vitamed Pharmaceuticals Sp. z o.o. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.
Net sales revenue
24.69%
Total operating revenue
28.97%
Operating profit (EBIT)
45.76%
EBITDA
38.92%
Net Profit (Loss) for the Period
56.12%
Total assets
21.14%
Total equity
22.54%
Operating Profit Margin (ROS)
2.82%
Net Profit Margin
3.21%
Return on Equity (ROE)
5.75%
Debt to Equity Ratio
-0.57%
Quick Ratio
-0.72%
Cash Ratio
-0.52%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?